124 related articles for article (PubMed ID: 37678429)
1. 6-hydroxydopamine affects multiple pathways to induce cytotoxicity in differentiated LUHMES dopaminergic neurons.
Ali N; Sane MS; Tang H; Compher J; McLaughlin Q; Jones CD; Maffi SK
Neurochem Int; 2023 Nov; 170():105608. PubMed ID: 37678429
[TBL] [Abstract][Full Text] [Related]
2. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
3. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
4. Peiminine Reduces ARTS-Mediated Degradation of XIAP by Modulating the PINK1/Parkin Pathway to Ameliorate 6-Hydroxydopamine Toxicity and α-Synuclein Accumulation in Parkinson's Disease Models In Vivo and In Vitro.
Hsu YL; Hung HS; Tsai CW; Liu SP; Chiang YT; Kuo YH; Shyu WC; Lin SZ; Fu RH
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638579
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic neurotoxicant 6-OHDA induces oxidative damage through proteolytic activation of PKCδ in cell culture and animal models of Parkinson's disease.
Latchoumycandane C; Anantharam V; Jin H; Kanthasamy A; Kanthasamy A
Toxicol Appl Pharmacol; 2011 Nov; 256(3):314-23. PubMed ID: 21846476
[TBL] [Abstract][Full Text] [Related]
6. 6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease.
Elkon H; Melamed E; Offen D
Cell Mol Neurobiol; 2001 Dec; 21(6):771-81. PubMed ID: 12043847
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the neuroprotective potential of caffeic acid phenethyl ester in a cellular model of Parkinson's disease.
Turan D; Abdik H; Sahin F; Avşar Abdik E
Eur J Pharmacol; 2020 Sep; 883():173342. PubMed ID: 32634439
[TBL] [Abstract][Full Text] [Related]
8. Influence of 6-Hydroxydopamine Toxicity on α-Synuclein Phosphorylation, Resting Vesicle Expression, and Vesicular Dopamine Release.
Ganapathy K; Datta I; Sowmithra S; Joshi P; Bhonde R
J Cell Biochem; 2016 Dec; 117(12):2719-2736. PubMed ID: 27064513
[TBL] [Abstract][Full Text] [Related]
9. Cell-based assays for Parkinson's disease using differentiated human LUHMES cells.
Zhang XM; Yin M; Zhang MH
Acta Pharmacol Sin; 2014 Jul; 35(7):945-56. PubMed ID: 24989254
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotection of inositol hexaphosphate and changes of mitochondrion mediated apoptotic pathway and α-synuclein aggregation in 6-OHDA induced parkinson's disease cell model.
Zhang Z; Hou L; Li X; Ju C; Zhang J; Li X; Wang X; Liu C; Lv Y; Wang Y
Brain Res; 2016 Feb; 1633():87-95. PubMed ID: 26740400
[TBL] [Abstract][Full Text] [Related]
11. Squamosamide derivative FLZ protected dopaminergic neuron by activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson's disease models.
Bao XQ; Kong XC; Kong LB; Wu LY; Sun H; Zhang D
Brain Res; 2014 Feb; 1547():49-57. PubMed ID: 24384139
[TBL] [Abstract][Full Text] [Related]
12. The Parkinson's disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity.
Batelli S; Invernizzi RW; Negro A; Calcagno E; Rodilossi S; Forloni G; Albani D
Neurodegener Dis; 2015; 15(1):13-23. PubMed ID: 25500798
[TBL] [Abstract][Full Text] [Related]
13. Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death.
Monti B; Polazzi E; Batti L; Crochemore C; Virgili M; Contestabile A
J Neurochem; 2007 Oct; 103(2):518-30. PubMed ID: 17635667
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
Chan WS; Durairajan SS; Lu JH; Wang Y; Xie LX; Kum WF; Koo I; Yung KK; Li M
Neurochem Int; 2009 Nov; 55(6):414-22. PubMed ID: 19409437
[TBL] [Abstract][Full Text] [Related]
15. Pathological α-synuclein accumulation, CSF metabolites changes and brain microstructures in cynomolgus monkeys treated with 6-hydroxydopamine.
Gan X; Ren J; Huang T; Wu K; Li S; Duan Y; Wang Z; Si W; Wei J
Neurotoxicology; 2023 Jan; 94():172-181. PubMed ID: 36476940
[TBL] [Abstract][Full Text] [Related]
16. Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson's disease.
Ikeda-Matsuo Y; Miyata H; Mizoguchi T; Ohama E; Naito Y; Uematsu S; Akira S; Sasaki Y; Tanabe M
Neurobiol Dis; 2019 Apr; 124():81-92. PubMed ID: 30423474
[TBL] [Abstract][Full Text] [Related]
17. Trib3 Is Elevated in Parkinson's Disease and Mediates Death in Parkinson's Disease Models.
Aimé P; Sun X; Zareen N; Rao A; Berman Z; Volpicelli-Daley L; Bernd P; Crary JF; Levy OA; Greene LA
J Neurosci; 2015 Jul; 35(30):10731-49. PubMed ID: 26224857
[TBL] [Abstract][Full Text] [Related]
18. 6-OHDA-Induced Changes in Parkinson's Disease-Related Gene Expression are not Affected by the Overexpression of PGAM5 in In Vitro Differentiated Embryonic Mesencephalic Cells.
Stępkowski TM; Wasyk I; Grzelak A; Kruszewski M
Cell Mol Neurobiol; 2015 Nov; 35(8):1137-47. PubMed ID: 25986246
[TBL] [Abstract][Full Text] [Related]
19. Extracellular Zn
Tamano H; Nishio R; Morioka H; Takeda A
Mol Neurobiol; 2019 Jan; 56(1):435-443. PubMed ID: 29705946
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
